REGENERON PHARMACEUTICALS, INC. (REGN) Stock Analysis

Analysis from 10-Q filed 2025-10-28. Data as of Q2 2026.

Overall Grade: F (Concerning)

Grade F (Concerning). ROIC 9.7%. FCF margin 24.2%. D/E 0.1x. Source: 10-Q filed 2025-10-28.

Metric	Value	Context
ROIC	9.7%	Near cost of capital
FCF Margin	24.2%	Strong cash generation
Debt/Equity	0.1x	Conservative leverage

ROIC 9.7% — Top 25% of sector peers. FCF margin 24.2% — Top 5%.

Explore REGENERON PHARMACEUTICALS, INC.: Earnings History | Filings

Programmatic access: Available via MCP at mcp.metricduck.com. Tools for REGN: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.

---

Profitability: REGENERON PHARMACEUTICALS, INC. earns 9.7% ROIC, Top 25% in Healthcare

ROIC TTM 9.7%, sector median -4.9%, Top 25%. DuPont: NOPAT margin 20.7% × asset turnover 0.4x. Gross margin 84.9%. Operating margin 24.7%. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
Return on Invested Capital (ROIC)	9.7%	Adequate	Above sector median of -4.9%
Return on Equity (ROE)	13.9%	Adequate	Moderate equity returns
Gross Margin	84.9%	Excellent	Strong pricing power
Operating Margin	24.7%	Excellent	Efficient operations

---

Cash Flow: REGENERON PHARMACEUTICALS, INC. generates $3.8B FCF at 24.2% margin, positive NaN/8 quarters

FCF TTM $3.8B. FCF margin 24.2%, Top 5%. OCF/Net income 1.1x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
Free Cash Flow Margin	24.2%	Excellent	Excellent cash conversion
Free Cash Flow (TTM)	$3.8B	Good	Positive cash generation
OCF/Net Income	1.1x	Excellent	High earnings quality
FCF Consistency (8Q)	N/A	Warning	Variable cash flow

---

Balance Sheet: REGENERON PHARMACEUTICALS, INC. at 0.1x leverage

Debt/Equity 0.1x. Net cash $6.0B. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
Debt to Equity	0.1x	Excellent	Conservative capital structure
Net Cash Position	$6.0B	Excellent	Net cash positive

---

Valuation: REGENERON PHARMACEUTICALS, INC. trades at 14.9x earnings

P/E 14.9x. EV/Sales 4.1x. FCF yield 5.8%. Dividend yield 0.6%. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
P/E Ratio	14.9x	Adequate	Reasonable valuation
EV/Sales	4.1x	Good	Growth premium priced in
FCF Yield	5.8%	Good	Attractive cash return
Dividend Yield	0.6%	Adequate	Growth focus over income

---

Capital Allocation: REGENERON PHARMACEUTICALS, INC. returns 5.7% shareholder yield

Total shareholder yield 5.7% (div 0.6% + buyback 5.1%). Capital returned $3.7B TTM. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
Total Shareholder Yield	5.7%	Good	Dividend + buyback yield combined
Buyback Yield	5.1%	Good	Active share repurchases
Total Capital Returned (TTM)	$3.7B	Good	Dividends + buybacks returned to shareholders

---

Sector Rankings

Metric	Value	Percentile	vs Median
Return on Invested Capital (ROIC)	9.7%	Top 25%	-
Free Cash Flow Margin	24.2%	Top 5%	-
Gross Margin	84.9%	Top 25%	1.3x above
Operating Margin	24.7%	Top 25%	12.3x above
Return on Equity (ROE)	13.9%	Top 50%	-
P/E Ratio	14.9x	N/A	-

---

Financial Scorecard

Metric	REGN	Rating	Sector Context
Return on Invested Capital (ROIC)	9.7%	Adequate	Top 25% of sector (median: -4.9%)
Free Cash Flow Margin	24.2%	Excellent	Top 5% of sector (median: 0.0%)
Gross Margin	84.9%	Excellent	Top 25% of sector (median: 64.6%)
Debt to Equity Ratio	6.3%	Excellent	Conservative capital structure
P/E Ratio (Price-to-Earnings)	14.9x	Adequate	Attractively valued
Free Cash Flow Yield	5.8%	Good	Solid cash yield

---

Frequently Asked Questions

Q: What is REGENERON PHARMACEUTICALS, INC.'s Return on Invested Capital (ROIC)?

REGENERON PHARMACEUTICALS, INC. (REGN) has a trailing twelve-month Return on Invested Capital (ROIC) of 9.7%. Sector median -4.9%. Source: 10-Q filed 2025-10-28.

Q: What is REGENERON PHARMACEUTICALS, INC.'s Free Cash Flow Margin?

REGENERON PHARMACEUTICALS, INC. (REGN) has a free cash flow margin of 24.2%, generating $3.8 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-28.

Q: What is REGENERON PHARMACEUTICALS, INC.'s P/E ratio and how does it compare to peers?

REGENERON PHARMACEUTICALS, INC. (REGN) trades at a P/E ratio of 14.9x, which is above the sector median of N/A. EV/Sales 4.1x. FCF yield 5.8%. Source: 10-Q filed 2025-10-28.

Q: Does REGENERON PHARMACEUTICALS, INC. pay a dividend?

REGENERON PHARMACEUTICALS, INC. (REGN) currently pays a dividend yield of 0.6%. Total shareholder yield (dividend + buybacks) 5.7%. Source: 10-Q filed 2025-10-28.

Q: What is REGENERON PHARMACEUTICALS, INC.'s revenue and earnings growth?

REGENERON PHARMACEUTICALS, INC. (REGN) grew revenue by 9.3% year-over-year. EPS +1.9% YoY. Source: 10-Q filed 2025-10-28.

Q: Is REGENERON PHARMACEUTICALS, INC. buying back stock?

REGENERON PHARMACEUTICALS, INC. (REGN) repurchased $3.3 billion of stock over the trailing twelve months. This represents a buyback yield of 5.1%. Source: 10-Q filed 2025-10-28.

Q: How does REGENERON PHARMACEUTICALS, INC. compare to competitors in Healthcare?

Compared to other companies in Healthcare, REGENERON PHARMACEUTICALS, INC. (REGN) shows: ROIC 9.7%, sector median -4.9% (Top 25%). FCF margin 24.2%, sector median 0.0% (Top 5%). Gross margin 84.9%, 20.3pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.

Q: What warning signs should I watch for with REGENERON PHARMACEUTICALS, INC.?

Quantitative warning flags for REGENERON PHARMACEUTICALS, INC. (REGN): 1) ROIC declining -2.3% over 8 quarters. Source: 10-Q filed 2025-10-28.

---

Data Source: Data sourced from 10-Q filed 2025-10-28. TTM metrics as of Q2 2026.

Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.

Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.

This analysis is for informational purposes only and does not constitute investment advice.